A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation (HSCT)

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

The purpose of the study is to assess PK, Pharmacodynamics (PD) and safety of pegcetacoplan in patients with TA-TMA after HSCT.

Phase 2

Swedish Orphan Biovitrum

Apellis Pharmaceuticals, Inc.